{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:34:10Z","timestamp":1790393650269,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Teclistamab and talquetamab treatments are typically initiated in a hospital due to the potential risk of cytokine release syndrome. However, emerging data support the potential for outpatient administration (i.e., administration without overnight hospital admission). An expert consensus survey and meeting were conducted among European specialists in multiple myeloma treatment to evaluate current and future outpatient administration with teclistamab and talquetamab in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All experts completed a 17\u2010question survey, participated in an individual follow\u2010up call, and attended an online consensus meeting in September 2024.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was strong agreement that outpatient treatment with teclistamab and talquetamab is feasible, with implementation already seen in some centers. Factors identified as potential criteria to define patient eligibility include cognitive status, caregiver presence, and distance from the hospital. While outpatient administration is not yet widely adopted due to limited experience with bispecific antibodies, the expert panel expects up to 50% of patients receiving teclistamab and talquetamab could be treated in an outpatient setting within 3\u2009years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Sharing best practices, robust protocol development, and evidence from clinical trials and real\u2010world experience will support the implementation of outpatient treatment with bispecific antibodies, which could relieve hospital resources and improve patients' treatment experience.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14444","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T23:48:50Z","timestamp":1750981730000},"page":"358-366","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions"],"prefix":"10.1111","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3509-3780","authenticated-orcid":false,"given":"Thomas","family":"Lund","sequence":"first","affiliation":[{"name":"Department of Hematology Odense University Hospital  Odense Denmark"},{"name":"Centre for Innovative Medical Technology (CIMT)  Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Khandanpour","sequence":"additional","affiliation":[{"name":"University Hospital Schleswig\u2010Holstein and University Cancer Center Schleswig\u2010Holstein, University of L\u00fcbeck  L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Anguille","sequence":"additional","affiliation":[{"name":"Division of Hematology Antwerp University Hospital  Edegem Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kisro","sequence":"additional","affiliation":[{"name":"L\u00fcbecker Onkologische Schwerpunktpraxis  L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Theresa","family":"Krauth","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division Hematology and Hemostaseology Medical University Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lund","sequence":"additional","affiliation":[{"name":"Karolinska Institute  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Nijhof","sequence":"additional","affiliation":[{"name":"St Antonius Hospital  Nieuwegein the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique M.","family":"Ocio","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital Marqu\u00e9s de Valdecilla (IDIVAL), University of Cantabria  Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC) University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Javelot","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Issy\u2010les\u2010Moulineaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Albrecht","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Issy\u2010les\u2010Moulineaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Entrala","family":"Cerezo","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[{"name":"Institut Universitaire du Cancer de Toulouse  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_2_10_9_1","unstructured":"European Medicines Agency \u201cTecvayli (Teclistamab) \u201daccessed August 19 2024 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecvayli."},{"key":"e_1_2_10_10_1","unstructured":"European Medicines Agency \u201cTalvey (Talquetamab) \u201daccessed August 19 2024 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/talvey."},{"key":"e_1_2_10_11_1","unstructured":"US Food and Drug Administration \u201cTECVAYLI (Teclistamab\u2010Cqyv) Injection for Subcutaneous Use \u201daccessed August 19 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761291s000lbl.pdf."},{"key":"e_1_2_10_12_1","unstructured":"US Food and Drug Administration \u201cTALVEY (Talquetamab\u2010Tgvs) Injection for Subcutaneous Use \u201daccessed August 19 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00385-5"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.05.003"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34756"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01666-5"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181228"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00043-3"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-022-00344-4"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-024-00524-4"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7517"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00963-y"},{"key":"e_1_2_10_23_1","unstructured":"A.Kowalski J.Lykon B.Diamond et\u00a0al. \u201cTocilizumab Prophylaxis for Patients With Relapsed or Refractory Multiple Myeloma Treated With Teclistamab Elranatamab or Talquetamab \u201d Paper Presented at 66th American Society of Hematology Annual Meeting and Exposition San Diego CA December 7\u201010 2024."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7528"},{"key":"e_1_2_10_25_1","doi-asserted-by":"crossref","unstructured":"C.Schinke R.Vij S.Jagannath et\u00a0al. \u201cProphylactic Tocilizumab to Mitigate Cytokine Release Syndrome in Patients Receiving Talquetamab for Relapsed\/Refractory Multiple Myeloma: Results From the Phase 1\/2 MonumenTAL\u20101 Study \u201d Paper Presented at 21st International Myeloma Society Annual Meeting Rio de Janeiro Brazil September 25\u201028 2024.","DOI":"10.1016\/S2152-2650(24)01980-3"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970688.75458.a8"},{"key":"e_1_2_10_27_1","unstructured":"National Comprehensive Cancer Network \u201cMultiple Myeloma (Version 2.2025) \u201daccessed May 14 2025 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187086"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185257"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204361"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01222-y"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174270"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970664.60500.7f"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179727"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1533"},{"key":"e_1_2_10_36_1","unstructured":"R.Bansal J.Paludo A.Corraes et\u00a0al. \u201cOutpatient Management of CAR\u2010T and Teclistamab for Patients With Lymphoma and Multiple Myeloma \u201d Paper Presented at 66th American Society of Hematology Annual Meeting and Exposition San Diego CA December 7\u201010 2023."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.11146"},{"key":"e_1_2_10_38_1","doi-asserted-by":"crossref","unstructured":"G.Fries A.Alshla A.Baran andB.Lipe \u201cTreatment Outcomes of Primary vs. Referred Patients With Multiple Myeloma Receiving Talquetamab or Teclistamab \u201d Paper Presented at 21st International Myeloma Society Annual Meeting Rio de Janeiro Brazil September 25\u201028 2024.","DOI":"10.1016\/S2152-2650(24)02022-6"},{"key":"e_1_2_10_39_1","doi-asserted-by":"crossref","unstructured":"R.Jiwani \u201cCan Bispecific T Cell Engagers for Multiple Myeloma Be Safely Administered in the Community? A Single Center Experience \u201d Paper Presented at 21st International Myeloma Society Annual Meeting Rio de Janeiro Brazil September 25\u201028 2024.","DOI":"10.1016\/S2152-2650(24)01938-4"},{"key":"e_1_2_10_40_1","doi-asserted-by":"crossref","unstructured":"S.Scott D.Roberts V.Gupta et\u00a0al. \u201cNSO\u201006 Protocol for Outpatient Administration of Multiple Myeloma Bispecific Antibodies Step\u2010Up Dosing \u201d Paper Presented at 21st International Myeloma Society Annual Meeting Rio de Janeiro Brazil September 25\u201028 2024.","DOI":"10.1016\/S2152-2650(24)02331-0"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.02.023"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00159-6"},{"key":"e_1_2_10_43_1","article-title":"Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization","author":"Puttkammer J. R.","year":"2025","journal-title":"JCO Oncol Pract"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T07:51:56Z","timestamp":1756799516000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/ejh.14444"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14444","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"2025-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}